对此，华熙生物表示根据我们的竞争情报分析，这一传言是基于一套标准的母内容模板，已经通过网络 水军散布了数年时间，并与不负责任的所谓"研报"形成了共振。一旦华熙生物有什么风吹草动，都会被 归结为"竞争失败"，归结为"透明质酸过时，重组胶原蛋白兴起"。但这些并不符合经营数据反映的真 相。 6月14日，华熙生物今日晚间发文《关于透明质酸和重组胶原蛋白的传言与真相》，再度回应近期与巨 子生物之间的风波。 有传言说华熙生物上述举措是基于"商战"，根本原因是华熙生物的透明质酸业务承压、重组胶原蛋白无 法与对手竞争，导致了业绩大幅下滑？ 华熙业绩下滑的主要原因其实是消费品业务下滑和一次性为了夯实资产质量而进行的资产减值带来的亏 损。如果没有这些亏损，华熙生物是一个盈利能力卓越的公司。另一方面，从竞争大图景看，最近一两 年业绩良好的公司也并非是重组胶原蛋白赛道兴起的原因，如一些电商运营能力强的企业一直都在领跑 护肤品业务的增长，而这一业务是基于复合配方而非单一成分。重组胶原这个赛道也有很多企业在亏 损，所以不能仅归因于某一赛道的兴起，还是因为这个领域有些C端企业一直保持着强运营的基因，在 这个问题上，我们跟市场上的传言有完全 ...

6月14日，华熙生物今日晚间发文《关于透明质酸和重组胶原蛋白的传言与真相》，再度回应近期风 波。 5月17日，华熙生物发布了"概念总在重演，科技永远向前"一文，质疑券商热捧重组胶原蛋白并非基于 科学逻辑。随后，市场出现了针对重组胶原蛋白产品学术概念及有效添加的质疑，华熙生物随后也表达 了支持这类讨论，提出反对成分"名称游戏"，这一系列举措的根本目的是什么？ 最后，从产业角度，华熙生物表示，"还没有看到这一领域有像透明质酸那样的成熟并高速发展的国际 市场，2024年中国的透明质酸出口量达到了161吨，其中医药级高端透明质酸出口了11.8吨。而同期， 重组胶原蛋白的出口量却不到0.02吨。所以，'重组胶原蛋白'正在取代'透明质酸'的传言在全球市场没 有原料消耗的数据支持。即便在资本概念切换中期待很高的国内市场，这种热度也是缺乏真实数据支持 的，我们非常了解市场上以重组胶原蛋白为概念的品牌采购了多少华熙生物的透明质酸和其他活性物， 也非常清楚其交叉检测的真实添加数据。" 责任编辑：陈钰嘉 华熙生物强调，近几年基于基因工程表达的重组胶原蛋白获得了快速发展，华熙生物也在从事相关的研 究和产业转化，华熙生物的重组胶原蛋白 ...

Group 1 - The core point of the news is that Langzi Co., Ltd. plans to reduce its stake in Ruoyuchen by up to 3% within 15 trading days, following a previous cash-out of 217 million yuan, indicating a strategic move to support its expanding medical beauty business [1][4][6] - Ruoyuchen's stock price has surged by 534% over the past year, with a year-to-date increase of over 150%, prompting Langzi's decision to sell at a high point [1][4] - Langzi's investment in Ruoyuchen has yielded over 8 times returns, marking it as one of its most successful financial investments in recent years [4][6] Group 2 - Ruoyuchen, founded in 2011 and listed in September 2020, has seen a significant shift in its business structure, with traditional e-commerce operations declining while its own brand business is on the rise [4][5] - The revenue from Ruoyuchen's self-owned brands has grown from 73.97 million yuan in 2021 to approximately 263 million yuan in 2023, accounting for nearly 19.27% of total revenue [5] - The overall gross margin for Ruoyuchen reached 44.57% in 2024, with self-owned brands achieving a gross margin of 67%, significantly higher than its other business segments [5] Group 3 - Langzi's medical beauty business has become its main revenue driver, contributing 2.784 billion yuan in 2024, which is 48.92% of total revenue, surpassing its fashion women's wear segment [9][10] - Despite the growth, the gross margin for the medical beauty segment is only 54.42%, which is lower than the 63.45% margin for the women's wear segment [9][10] - Langzi's short-term borrowings have surged by 92.11% year-on-year, indicating increasing financial pressure as it expands its medical beauty operations [9][14] Group 4 - Langzi has faced compliance issues within its medical beauty operations, with several institutions under its umbrella encountering penalties for various violations [13] - The company is actively seeking funding to support its medical beauty expansion, which may include repaying upcoming debts and acquiring regional medical beauty institutions [13][14] - The medical beauty market in China has significant growth potential, with a penetration rate of only 3%-5%, compared to 20% in South Korea, but faces challenges from competitors and macroeconomic fluctuations [13][14]

Core Viewpoint - The controversy surrounding the cosmetic brand "Kefumei" and its alleged false advertising of a collagen product has escalated, leading to significant public attention and legal implications for the involved parties [1][3]. Group 1: Company Responses - "Giant Bio" issued a statement acknowledging the apology from the testing agency used by "Dr. Big Mouth" and emphasized that the agency did not authorize the testing report [4]. - "Giant Bio" reiterated that their product contains real recombinant collagen protein and denied any allegations of false advertising or misleading consumers [5]. - "Huaxi Bio" publicly supported "Dr. Big Mouth," stating that the company is an important member of its ecosystem and has invested in related ventures [4]. Group 2: Influencer Background - "Dr. Big Mouth," whose real name is Hao Yu, is a well-known beauty influencer with over 2.8 million followers across various platforms and holds a PhD in chemistry from the University of Hong Kong [3]. - The influencer's allegations against "Giant Bio" regarding the authenticity of their collagen product gained significant traction, even trending on social media [3]. Group 3: Legal and Regulatory Implications - "Giant Bio" announced intentions to pursue legal action against those spreading false information, highlighting the seriousness of the allegations and the potential impact on their brand [4]. - The testing agency involved has demanded that "Dr. Big Mouth" cease using and sharing the disputed test report to prevent further public misinformation [4].

Group 1: Market Trends and Insights - The Chinese beauty market's retail sales reached 30.9 billion yuan in April, with a year-on-year growth of 7.2%. The trend is shifting from short-term traffic chasing to focusing on brand value, with domestic brands like Proya and Chando gaining recognition due to their technological and branding advantages [1] - The sunscreen market in China is expected to exceed 36 billion yuan by 2025, driven by the increasing demand for comprehensive solutions that address various skincare needs. New products from brands like Shiseido and L'Oréal are focusing on innovative formulations and user experiences [3] - The body care market in China is projected to grow at a compound annual growth rate of 6.4% from 2024 to 2028, with a market size expected to surpass 37.8 billion yuan by 2028. Key trends include the upgrade of body care products to match facial skincare standards and the rise of emotional economy through fragrance products [5] Group 2: Financial Performance and Corporate Developments - In the first quarter of 2025, international beauty companies showed significant performance divergence, with major players like Procter & Gamble and Estée Lauder experiencing revenue declines due to economic downturns and market pressures. In contrast, smaller companies demonstrated resilience and growth [8] - Yatsen E-commerce reported a strong Q1 2025 revenue of 834 million yuan, a 7.8% year-on-year increase, driven by its skincare segment, which accounted for 43.5% of total revenue. The overall gross margin improved to 79.1% due to product structure optimization [13] - The beauty platform Dewu achieved a GMV exceeding 10 billion yuan, with brands like Han Shu and Winona benefiting from its unique business model, which includes a high percentage of free traffic and low return rates [11]

Core Insights - The medical beauty industry in China is projected to grow, with a consumption penetration rate increasing from 3.2% in 2020 to 5.8% by 2025, indicating over 80 million people have undergone medical beauty procedures [1] - The brand "可复美" (Kefumei) under 巨子生物 (Giant Bio) is facing significant negative publicity due to allegations of product fraud related to its key ingredient, recombinant collagen [2][3] - The controversy has led to a substantial decline in Giant Bio's stock price, dropping nearly 30% from its peak of 87.1 HKD [3][25] Industry Overview - The medical beauty market is expanding rapidly, with a notable increase in consumer engagement and product usage [1] - The competitive landscape is intensifying, particularly with rival companies like 华熙生物 (Huaxi Bio) actively targeting Giant Bio amid the ongoing controversies [4][5] Company Performance - Giant Bio's revenue grew from 20 billion RMB in 2022 to 35.24 billion RMB in 2023, marking a 49.05% increase, and further to 55.39 billion RMB in 2024, with a 57.2% year-on-year growth [25] - Despite strong revenue growth, the company has faced challenges in maintaining investor confidence due to recent scandals, leading to a market capitalization drop of over 60 billion HKD [3][25] Product Controversies - The allegations against Kefumei include claims that the amount of recombinant collagen in its products is significantly lower than advertised, raising questions about product integrity [3][6] - Previous controversies involved undisclosed ingredients like epidermal growth factor (EGF), which is banned in cosmetic products, further complicating the brand's reputation [10][12][17] Market Dynamics - The ongoing disputes have prompted consumers to reconsider their loyalty to Kefumei, with potential shifts towards alternative brands like 修丽可 (Xiu Li Ke) and 敷尔佳 (Fu Er Jia) [27] - The company's reliance on sales and marketing over research and development is evident, with a stark contrast between sales expenses and R&D investment, which may impact long-term sustainability [28][29]

Core Points - The 2025 Shandong Province Foreign Trade Quality Products Shopping Season's fourth phase for crafts, gifts, and decorative items was launched on June 13, emphasizing the theme "Foreign Trade Quality Products, Quality Enjoyment in Qilu" [1] - The event aims to implement strategies for expanding domestic demand, promoting the integration of domestic and foreign trade, and facilitating the transformation and upgrading of foreign trade enterprises [1] Group 1 - The "Integration of Domestic and Foreign Trade Action" was officially launched during the opening ceremony, aiming to create a "brand rise ecological circle" that promotes the collaborative development of time-honored domestic brands and foreign trade quality products [3] - A memorandum for the national market integration development of Shandong foreign trade quality products was signed by cultural export bases and associations from various provinces, indicating a commitment to collaborative growth [3] - The Shandong Province Time-Honored Brand Association initiated a supply chain co-construction action to innovate and integrate national brands with foreign trade quality products [3] Group 2 - The exhibition area highlighted various cultural export bases and showcased the charm of Shandong's craft industry, with interactive zones attracting significant public interest [6] - Leading brands such as Qingdao Jifa, Century Kaiyuan, and others presented their products that meet international standards, drawing attention from numerous buyers and citizens [6] - The event featured hands-on experiences in traditional crafts, enhancing public engagement and appreciation for local craftsmanship [6] Group 3 - To improve supply and demand matching efficiency, specialized procurement matchmaking meetings and e-commerce selection events were organized, gathering diverse purchasing forces [8] - Major procurement entities provided insights into their purchasing needs and channel advantages, leading to preliminary cooperation intentions with various enterprises [8] - The event also addressed the digital transformation needs of enterprises by inviting organizations to present their procurement requirements, thereby accelerating domestic sales [8] Group 4 - The Shandong Provincial Department of Commerce emphasized that the continuous hosting of the foreign trade quality products shopping festival series is crucial for promoting the integration of domestic and foreign trade and assisting foreign trade enterprises in their transformation [10] - The event will run until June 17, inviting consumers and buyers to participate and enjoy quality foreign trade products [10]

Core Viewpoint - The controversy surrounding the collagen product "Kefumei" and its alleged false claims has led to significant media attention and a public dispute between two major players in the beauty and medical aesthetics industry, Juzhibio and Huaxi Biological. Group 1: Allegations and Responses - The beauty blogger "Dr. Big Mouth" raised concerns about the collagen content in "Kefumei" products, claiming it was only 0.02%, below the regulatory threshold of 0.1% [5] - Juzhibio, the parent company of "Kefumei," denied these allegations, asserting that their internal tests showed collagen content exceeding 0.1%, with third-party tests indicating levels between 0.2% and 0.22% [8] - The blogger's videos related to Juzhibio were removed from social media platforms, which he attributed to malicious reporting rather than voluntary deletion [1] Group 2: Industry Dynamics - The dispute is seen as a competitive clash between Juzhibio and Huaxi Biological, with the latter supporting the blogger's claims and hinting at a potential "business war" [8] - Juzhibio's market capitalization is reported to be over twice that of Huaxi Biological, despite similar performance levels, indicating a market preference for Juzhibio's collagen products [8] - Huaxi Biological had previously attempted to enter the collagen market through acquisitions, indicating a strategic interest in this segment [9] Group 3: Market Impact - Following the public dispute, both Juzhibio and Huaxi Biological experienced stock price declines, with Juzhibio opening at 59.8 HKD per share and Huaxi Biological at 54.34 CNY per share [11]

Core Viewpoint - The article discusses the ongoing competition between two major players in the medical beauty industry, Huaxi Biological and Juzhi Biological, highlighting the market dynamics and the impact of recent controversies on their valuations and reputations [4][12][44]. Group 1: Market Dynamics - Huaxi Biological publicly criticized the notion that hyaluronic acid is outdated, directly targeting nine brokerage firms for their lack of rigor in research reports, which favored Juzhi Biological [4][12]. - Juzhi Biological's market capitalization has decreased significantly, dropping to approximately HKD 65 billion, a nearly one-third reduction from its peak on May 20 [8][46]. - The medical beauty market is experiencing rapid changes, with Juzhi Biological's revenue surpassing Huaxi Biological's in 2024, and its net profit being nearly twelve times that of Huaxi Biological [12][44]. Group 2: Controversies and Responses - Juzhi Biological faced allegations of product ingredient fraud, specifically regarding its core product, Kefu Mei, which is crucial for its revenue [6][29]. - The company initially responded slowly to the allegations, which led to investor dissatisfaction and a significant drop in stock price [28][29]. - Despite attempts to clarify the situation through third-party testing, Juzhi Biological's responses have been met with skepticism, particularly regarding the validity of their testing methods [26][27]. Group 3: Competitive Landscape - The competition between Huaxi Biological and Juzhi Biological is characterized as a market "replacement," with both companies vying for dominance in the medical beauty sector [13][44]. - Huaxi Biological's management attributes the market shift to capital chasing new trends, particularly the rise of collagen products over hyaluronic acid [44][45]. - The article emphasizes the fragility of the business models in the medical beauty industry, as both companies heavily rely on specific products, making them vulnerable to market changes [47][48].

Core Insights - The report emphasizes the importance of proactive discovery in the financial market rather than merely relaying information [1] Domestic Financial Market - The Shanghai Composite Index closed at 3402.66, with a slight increase of 0.01% [3] - The Shenzhen Component Index closed at 10234.33, showing a decrease of 0.11% [3] - The ChiNext Index closed at 2067.15, reflecting an increase of 0.26% [3] - The Hang Seng Futures Index closed at 31013.11, with a decline of 1.2% [3] Macro News Summary - The central bank and foreign exchange bureau are increasing financial support for cross-strait integration development [5] - The Ministry of Industry and Information Technology supports automotive companies in adhering to a payment term of no more than 60 days [5] - The National Development and Reform Commission emphasizes the coordination of economic reforms with education, technology, and talent [5] Industry Latest Developments - A solid-state battery conference is scheduled for next week, indicating the industry is on the verge of mass production, with related stocks including Honggong Technology and Guoxuan High-Tech [6] - The biomanufacturing sector is receiving policy support for the establishment of pilot platforms, with related stocks including Huaxi Biological and Chuaning Biological [6] - The stablecoin market is experiencing rapid growth, with increasing activity in cross-border payment applications, related stocks include Newland and Dongxin Peace [6] Company Focus - Xidian Co., Ltd. is the first domestic company to achieve industrial application of 12-inch wafer probe stations [7] - Antarctic Light is currently the only LCD backlight module supplier certified by Nintendo, maintaining a stable position in the Switch 2 backlight module supply [7] - Jin Modern has adapted its low-code development platform to the DeepSeek large model [7] - Lanshi Heavy Industry's wholly-owned subsidiary plans to acquire 100% equity of Qingdao Equipment for 99.9821 million yuan, enhancing its nuclear equipment manufacturing capabilities [7] Market Review and Outlook - On June 12, the market opened slightly lower and exhibited a fluctuating pattern, with the Shanghai Composite Index briefly falling below 3400 points before recovering [8] - The total trading volume in the Shanghai and Shenzhen markets reached 1.27 trillion yuan, an increase of 16.3 billion yuan from the previous trading day [8] - Sectors with notable gains included precious metals, beauty care, jewelry, diversified finance, and cultural media, while shipping ports, liquor, electronic chemicals, and coal sectors faced declines [8] - The report indicates a cautious outlook for the market, with a potential for further consolidation, while maintaining a bullish medium-term perspective [8]